Mené sur 301 garçons et 971 filles âgés de 9 à 15 ans et ayant reçu 3 doses de vaccin nonavalent contre le papillomavirus humain (HPV), cet essai multicentrique de phase III évalue l'immunogénicité, l'innocuité et l'efficacité du vaccin 9vHPV jusqu'à 11 ans après la vaccination

Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety

Restrepo, Jaime ; Herrera, Teobaldo ; Samakoses, Rudiwilai ; Reina, Julio C. ; Pitisuttithum, Punnee ; Ulied, Angels ; Bekker, Linda-Gail ; Moreira, Edson D. ; Olsson, Sven-Eric ; Block, Stan L. ; Hammes, Luciano S. ; Laginha, Fabio ; Ferenczy, Alex ; Kurman, Robert ; Ronnett, Brigitte M. ; Stoler, Mark ; Bautista, Oliver ; Gallagher, Nancy E. ; Salituro, Gino ; Ye, Min ; Luxembourg, Alain

The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity study in 9- to 15-year-old boys and girls was extended to assess immunogenicity and effectiveness through 10 years after the last vaccine dose (NCT00943722).Boys (n = 301) and girls (n = 971) who received three 9vHPV vaccine doses in the base study (day 1, months 2 and 6) enrolled in the extension. Serum was collected through month 126 for antibody assessments by competitive Luminex immunoassay and immunoglobulin [...]

A partir d'une revue systématique de la littérature publiée jusqu'en mars 2022 (158 articles), cette étude analyse les données concernant l'intérêt d'une salpingectomie bilatérale pour prévenir un cancer de l'ovaire

Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review

Kahn, Ryan M. ; Gordhandas, Sushmita ; Godwin, Kendra ; Stone, Rebecca L. ; Worley, Michael J., Jr ; Lu, Karen H. ; Long Roche, Kara C.

Most ovarian cancers originate in the fimbriated end of the fallopian tube. This has led to the hypothesis that surgical resection of the fallopian tubes at the time of gynecologic and nongynecologic surgical procedures—referred to as an opportunistic salpingectomy—may prevent the development of epithelial ovarian cancer for women at an average risk of developing the disease.To compile a comprehensive, state-of-the-science review examining the current landscape of performing bilateral [...]

Menée aux Etats-Unis entre 2018 et 2020 sur 188 fumeurs (âge moyen : 49 ans ; 54 % de femmes), cet essai randomisé évalue l'efficacité, du point de vue de l'abstinence tabagique pendant 30 jours, d'un traitement adaptatif d'aide au sevrage tabagique par rapport à un traitement standard (non adaptatif)

Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial

Davis, James M. ; Masclans, Luisa ; Rose, Jed E.

Adaptive pharmacotherapy, ie, starting a medication regimen and then modifying that regimen based on patient response, is common in many medical domains but is not common in smoking cessation. Recently, studies have found that adaptive treatment using precessation nicotine patches is efficacious for smoking cessation; however, adaptive treatment using precessation varenicline and adaptive treatment in clinical practice settings have not been fully assessed.To determine whether adaptive [...]